Literature DB >> 23523670

Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types.

Ágnes Holczbauer1, Valentina M Factor1, Jesper B Andersen1, Jens U Marquardt1, David E Kleiner2, Chiara Raggi1, Mitsuteru Kitade1, Daekwan Seo1, Hirofumi Akita1, Marian E Durkin1, Snorri S Thorgeirsson3.   

Abstract

BACKGROUND & AIMS: Human primary liver cancer is classified into biologically distinct subgroups based on cellular origin. Liver cancer stem cells (CSCs) have been recently described. We investigated the ability of distinct lineages of hepatic cells to become liver CSCs and the phenotypic and genetic heterogeneity of primary liver cancer.
METHODS: We transduced mouse primary hepatic progenitor cells, lineage-committed hepatoblasts, and differentiated adult hepatocytes with transgenes encoding oncogenic H-Ras and SV40LT. The CSC properties of transduced cells and their ability to form tumors were tested by standard in vitro and in vivo assays and transcriptome profiling.
RESULTS: Irrespective of origin, all transduced cells acquired markers of CSC/progenitor cells, side populations, and self-renewal capacity in vitro. They also formed a broad spectrum of liver tumors, ranging from cholangiocarcinoma to hepatocellular carcinoma, which resembled human liver tumors, based on genomic and histologic analyses. The tumor cells coexpressed hepatocyte (hepatocyte nuclear factor 4α), progenitor/biliary (keratin 19, epithelial cell adhesion molecule, A6), and mesenchymal (vimentin) markers and showed dysregulation of genes that control the epithelial-mesenchymal transition. Gene expression analyses could distinguish tumors of different cellular origin, indicating the contribution of lineage stage-dependent genetic changes to malignant transformation. Activation of c-Myc and its target genes was required to reprogram adult hepatocytes into CSCs and for tumors to develop. Stable knockdown of c-Myc in transformed adult hepatocytes reduced their CSC properties in vitro and suppressed growth of tumors in immunodeficient mice.
CONCLUSIONS: Any cell type in the mouse hepatic lineage can undergo oncogenic reprogramming into a CSC by activating different cell type-specific pathways. Identification of common and cell of origin-specific phenotypic and genetic changes could provide new therapeutic targets for liver cancer.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23523670      PMCID: PMC3913051          DOI: 10.1053/j.gastro.2013.03.013

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  47 in total

Review 1.  Liver stem cells and their implication in hepatocellular and cholangiocarcinoma.

Authors:  T Roskams
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

2.  Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties.

Authors:  Tetsuhiro Chiba; Kaoru Kita; Yun-Wen Zheng; Osamu Yokosuka; Hiromitsu Saisho; Atsushi Iwama; Hiromitsu Nakauchi; Hideki Taniguchi
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

Review 3.  Conditional transgenic models define how MYC initiates and maintains tumorigenesis.

Authors:  Constadina Arvanitis; Dean W Felsher
Journal:  Semin Cancer Biol       Date:  2006-07-21       Impact factor: 15.707

4.  The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis.

Authors:  Li Xin; Devon A Lawson; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-28       Impact factor: 11.205

5.  A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis.

Authors:  Soledad R Alonso; Lorraine Tracey; Pablo Ortiz; Beatriz Pérez-Gómez; José Palacios; Marina Pollán; Juan Linares; Salvio Serrano; Ana I Sáez-Castillo; Lydia Sánchez; Raquel Pajares; Abel Sánchez-Aguilera; Maria J Artiga; Miguel A Piris; José L Rodríguez-Peralto
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

6.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

7.  Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors.

Authors:  L Zender; W Xue; C Cordón-Cardo; G J Hannon; R Lucito; S Powers; P Flemming; M S Spector; S W Lowe
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2005

8.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells.

Authors:  Stephanie Ma; Kwok-Wah Chan; Liang Hu; Terence Kin-Wah Lee; Jana Yim-Hung Wo; Irene Oi-Lin Ng; Bo-Jian Zheng; Xin-Yuan Guan
Journal:  Gastroenterology       Date:  2007-04-15       Impact factor: 22.682

9.  Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes.

Authors:  Tan A Ince; Andrea L Richardson; George W Bell; Maki Saitoh; Samuel Godar; Antoine E Karnoub; James D Iglehart; Robert A Weinberg
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

10.  Module map of stem cell genes guides creation of epithelial cancer stem cells.

Authors:  David J Wong; Helen Liu; Todd W Ridky; David Cassarino; Eran Segal; Howard Y Chang
Journal:  Cell Stem Cell       Date:  2008-04-10       Impact factor: 24.633

View more
  62 in total

1.  Buffalo liver transcriptome analysis suggests immune tolerance as its key adaptive mechanism during early postpartum negative energy balance.

Authors:  Sudhakar Singh; Naresh Golla; Davinder Sharma; Dheer Singh; Suneel Kumar Onteru
Journal:  Funct Integr Genomics       Date:  2019-05-09       Impact factor: 3.410

Review 2.  Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress.

Authors:  Elizabeth M Brunt; Valerie Paradis; Christine Sempoux; Neil D Theise
Journal:  Hepat Oncol       Date:  2015-07-28

3.  Hepatic stem cells and cancers: a pathologist's view.

Authors:  Neil D Theise
Journal:  Hepat Oncol       Date:  2015-10

Review 4.  [Diagnostics and treatment of cholangiocellular carcinoma].

Authors:  L Zender; N P Malek
Journal:  Internist (Berl)       Date:  2016-12       Impact factor: 0.743

5.  IDH mutations in liver cell plasticity and biliary cancer.

Authors:  Supriya K Saha; Christine A Parachoniak; Nabeel Bardeesy
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  Lineage fate of ductular reactions in liver injury and carcinogenesis.

Authors:  Simone Jörs; Petia Jeliazkova; Marc Ringelhan; Julian Thalhammer; Stephanie Dürl; Jorge Ferrer; Maike Sander; Mathias Heikenwalder; Roland M Schmid; Jens T Siveke; Fabian Geisler
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

Review 7.  Emerging roles of Notch signaling in liver disease.

Authors:  Fabian Geisler; Mario Strazzabosco
Journal:  Hepatology       Date:  2014-09-19       Impact factor: 17.425

Review 8.  Functional and genetic deconstruction of the cellular origin in liver cancer.

Authors:  Jens U Marquardt; Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

Review 9.  Research progress and prospects of markers for liver cancer stem cells.

Authors:  Cheng-Pei Zhu; An-Qiang Wang; Hao-Hai Zhang; Xue-Shuai Wan; Xiao-Bo Yang; Shu-Guang Chen; Hai-Tao Zhao
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

10.  Liver cancer oncogenomics: opportunities and dilemmas for clinical applications.

Authors:  Jens U Marquardt; Jesper B Andersen
Journal:  Hepat Oncol       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.